Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the best stocks under $5 with highest upside potential. On October 28, Needham lifted its price target on Neumora Therapeutics, Inc. (NASDAQ:NMRA) to $8 from $6 while keeping a Buy rating on the stock. The firm told investors that it is more optimistic about the company’s outlook after its R&D Investor Event that exhibited its broad pipeline.

5 Fastest Growing Biotech Companies in the US

Similarly, Guggenheim upgraded Neumora Therapeutics, Inc. (NASDAQ:NMRA) to Buy from Neutral on October 27, setting a $14 price target on the shares. The firm told investors that it released the rating update after the “compelling” preclinical obesity data reported by Neumora Therapeutics, Inc. (NASDAQ:NMRA). Guggenheim added that it believes the company’s NLRP3i program in obesity and related disorders to be “a clear driver to value creation.”

Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a clinical-stage biotechnology company that integrates neuroscience and data science to offer a precision medicine approach for brain diseases. Its focus is on advancing medicines for therapeutically relevant targets implicated in CNS diseases.

While we acknowledge the potential of NMRA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NMRA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.